The European Society for Blood and Marrow Transplantation (EBMT) 2021

Clinical Burden of Illness Survey Results for U.S. Patients with Paroxysmal Nocturnal Hemoglobinuria Receiving C5 Inhibitors

Access Resources

Improvements in Fatigue and Physical Function Evaluated Through Changes in Clinical Outcomes in Paroxysmal Nocturnal Hemoglobinuria: Post-Hoc Analyses from the PEGASUS Study

Access Resources

Injection-Site Reactions in the Randomized Phase 3 PEGASUS Trial of Pegcetacoplan Compared With Eculizumab for Individuals With Paroxysmal Nocturnal Hemoglobinuria

Access Resources

Work Productivity Loss and Quality of Life in Paroxysmal Nocturnal Hemoglobinuria Among Patients Receiving C5 Inhibitors in the United States

Access Resources

Back to Conference Resources

PNH Congress Presentations

The following information is available for educational purposes only. The information is not to be re-purposed or re-used in its current form or presentation for any personal or professional use. Apellis reserves the right to withdraw, modify or change the information that is available on this website at any time.